The evolving role of chemotherapy in prostate cancer

被引：0
作者：
De Wit, R. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：21 / 21
页数：1
相关论文
共 3 条
[1]   Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy [J].
de Wit, R .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (04) :502-507
[2]   Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].
Petrylak, DP ;
Tangen, CM ;
Hussain, MHA ;
Lara, PN,J ;
Jones, JA ;
Taplin, ME ;
Burch, PA ;
Berry, D ;
Moinpour, C ;
Kohli, M ;
Benson, MC ;
Small, EJ ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520
[3]   Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [J].
Tannock, IF ;
de Wit, R ;
Berry, WR ;
Horti, J ;
Pluzanska, A ;
Chi, KN ;
Oudard, S ;
Theodore, C ;
James, ND ;
Turesson, I ;
Rosenthal, MA ;
Eisenberger, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1502-1512
1